OncoMatch/Clinical Trials/NCT05351502
A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Primary or Metastatic Tumors
Is NCT05351502 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Nitric Oxide 25,000 ppm and Nitric Oxide 50,000 ppm for cancer.
Treatment: Nitric Oxide 25,000 ppm · Nitric Oxide 50,000 ppm · Nitric Oxide 100,000 ppm · Nitric Oxide selected dose — This is a Phase 1, open-label, dose-escalation and dose-expansion study comprised of a screening period, a single treatment session, an evaluation period of 21±3 days, and safety and survival follow-up period of up to 12 weeks post-treatment.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Cannot have received: systemic anti-cancer therapy
Has received prior systemic anti-cancer therapy including investigational agents within 14 days of the start of study treatment
Cannot have received: radiotherapy
Exception: to the targeted lesions within the preceding 12 months
have not had radiotherapy to the targeted lesions within the preceding 12 months
Lab requirements
Blood counts
adequate hematologic function
Kidney function
adequate organ function
Liver function
adequate organ function
Patient have adequate hematologic and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify